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Recently, a series of studies explored the correlation between the neutrophil to lymphocyte ratio and the
prognosis of lung cancer. However, the current opinion regarding the prognostic role of the neutrophil to
lymphocyte ratio in lung cancer is inconsistent.
We performed a meta-analysis of published articles to investigate the prognostic value of the neutrophil to
lymphocyte ratio in lung cancer. The hazard ratio (HR) and its 95% confidence interval (CI) were calculated.
An elevated neutrophil to lymphocyte ratio predicted worse overall survival, with a pooled HR of 1.243 (95%CI:
1.106-1.397; Pheterogeneity=0.001) from multivariate studies and 1.867 (95%CI: 1.487-2.344; Pheterogeneity=0.047)
from univariate studies. Subgroup analysis showed that a high neutrophil to lymphocyte ratio yielded worse
overall survival in non-small cell lung cancer (NSCLC) (HR=1.192, 95%CI: 1.061-1.399; Pheterogeneity=0.003) as well
as small cell lung cancer (SCLC) (HR=1.550, 95% CI: 1.156-2.077; Pheterogeneity=0.625) in multivariate studies.
The synthesized evidence from this meta-analysis of published articles demonstrated that an elevated neutrophil
to lymphocyte ratio was a predictor of poor overall survival in patients with lung cancer.
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’ INTRODUCTION
Lung cancer is one of the leading causes of cancer-related
deaths (1,2). Non-small cell lung cancer (NSCLC) accounts
for approximately 85% of lung cancer cases, and small-cell
lung cancer (SCLC) accounts for nearly 13% of overall lung
cancer cases. Despite continue efforts and progress in
diagnosis and treatment, the overall survival (OS) for lung
cancer patients remains poor (1,2). Prognostic factors
influencing survival have been previously identified, includ-
ing tumor stage, performance status, weight loss, age, sex,
histopathology, and plasma lactate dehydrogenase (LDH)
and carcinoembryonic antigen (CEA) levels (3-7). Although
novel immunological and histological biomarkers such as
intercellular adhesion molecule-1 (IDM-1) and epidermal
growth factor receptor (EGFR) have been identified (8,9),
these marks are expensive and often time-consuming to
measure. Thus, there remains no promising prognostic factor
that can be easily detected and closely linked to clinical
outcomes for lung cancer patients (10).
The tumor immune environment plays an important role
in tumor progression by promoting tumor angiogenesis,
tumor metastasis, and cancer cell proliferation and by
interfering with the response to systemic treatment (11,12).
Neutrophils and T and B lymphocytes have been suggested
to play vital roles in tumor inflammation (13,14), and the
imbalance between neutrophils and lymphocytes is thought
to be secondary to tumor hypoxia or necrosis and associated
with anti-apoptotic effects (15). The neutrophil to lympho-
cyte ratio (NLR), representing a combination of circulating
neutrophil and lymphocyte counts, can reflect the imbalance
between neutrophils and lymphocytes in patients with
tumors and serves as a representative index of systemic
inflammation.
Recently, an elevated preoperative or pretreatment NLR,
calculated from peripheral blood tests, was identified as an
independent and readily available prognostic biomarker
related to poor survival in numerous cancers, including
colorectal cancer, breast cancer, gastric cancer and esopha-
geal cancer (16-19). Additionally, a series of studies have
explored the correlation between the NLR and the prognosis
of lung cancer. However, according to their results, theDOI: 10.6061/clinics/2015(07)10
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current opinion on the prognostic role of the NLR in lung
cancer is inconsistent and inconclusive. Thus, we performed
this meta-analysis, which is the first systematic study on the
subject, to investigate the prognostic value of the NLR in
lung cancer.
’ MATERIALS AND METHODS
Search strategy and study selection
To identify eligible studies regarding the NLR for predicting
the prognosis of lung cancer, a systematic review was
conducted. Relevant studies were identified by searching the
PubMed and Web of Science databases using the following
search terms: NLR, neutrophil-to-lymphocyte ratio, neutrophil
lymphocyte ratio or neutrophil-lymphocyte ratio with lung
cancer, carcinoma of the lung, pulmonary carcinoma and
prognosis, prognostic, survival or outcome. The last search was
updated on October 31, 2014. Both Medical subheadings
(MeSH) and free text terms were used as keywords. The
reference lists of papers of interest and published review
articles were also explored to potentially retrieve additional
studies. The inclusion criteria for the studies were as follows: (a)
provided clear information on lung cancer confirmation and
the included patients; (b) investigated the association of the pre-
treatment NLR with OS; and (c) full text articles in English. The
exclusion criteria were as follows: (a) letters, reviews, expert
opinions, case reports or laboratory studies; (b) studies with
overlapping or duplicate data; and (c) a lack of key information
for evaluating the hazard ratio (HR) for further analysis.
Data extraction
All searches were conducted independently by two
investigators. The same two authors independently extracted
data on the name of the first author, the year of publication,
the country of origin, ethnicity, the total number of cases,
cancer types, stages, cut-off values, follow ups and HRs of
the NLR for OS with 95% confidence intervals (CIs). Any
discrepancy was resolved by consensus and, if needed, by
consultation with the third author.
Statistical analysis
OS results were evaluated as HRs for each included study.
HRs and 95% CIs were obtained directly from each publication.
If not available, the necessary data were extracted to calculate
the HR using the method reported by Tierney et al. (20). The
heterogeneity of pooled results was estimated using Cochran’s
Q test and Higgins’ I-squared statistic. A p-valueo0.10 for the
Q-test indicated significant heterogeneity, and a random-effects
model (DerSimonian-Laird method) was used to calculate the
pooled HRs (21). Otherwise, a fixed-effects model (Mantel-
Haenszel method) was applied (22). Egger’s linear regression
and Begg’s funnel plot test were applied to evaluate publication
bias in the literature, and a p-value o0.05 was considered
significant. A trim and fill method was performed to estimate
asymmetry in the funnel plot. Meta-regression was performed
to explore the potential source of heterogeneity using variables
such as the year of publication, ethnicity, cancer type, cutoff
value and sample size. To validate the credibility of outcomes
in this meta-analysis, sensitivity analysis was performed by
sequential omission of each individual study using the
‘‘metainf’’ STATA command. All statistical analyses were
conducted with STATA software version 12.0 (STATA Corpora-
tion, College Station, TX, USA), and all p-values were two-
sided.
’ RESULTS
Study characteristics
We identified fourteen studies according to the inclusion
and exclusion criteria (23-36). The detailed screening process
is shown in Figure 1. All of these articles were published in
English. The characteristics of the included studies are shown
in Table 1. Three studies were performed in China and Japan,
whereas two each were performed in the USA, UK and
Turkey and one each in Spain and Korea. Among the
included studies, participants were Asian in seven studies
and Caucasian in the other seven studies. A total of twelve
studies explored the NLR in the prognosis of NSCLC, and
two studies explored the NLR in SCLC. The cut-off value
used in each study was not consistent, ranging from 2.5 to
5.0. The number of patients in each study ranged from 59 to
388. Six studies calculated HRs by multivariate analysis, five
studies calculated HRs by univariate analysis, and the other
three studies calculated HRs by both multivariate and
univariate analyses. In total, nine studies contained HRs
calculated from multivariate analysis, and eight studies
contained HRs calculated from univariate analysis.
Outcome from eligible studies
As shown in Table 2, fourteen studies evaluating OS were
classified into two groups: nine multivariate studies with HRs
and 95% CIs acquired from multivariate analysis, and eight
univariate studies with data from univariate analysis. In both
the multivariate and univariate analysis groups, an elevated
NLR predicted a worse outcome of OS, with a pooled HR of
1.243 (95%CI: 1.106-1.397; Pheterogeneity=0.001) and 1.867 (95%
CI: 1.487-2.344; Pheterogeneity=0.047), respectively (Figure 2).
Subgroup analysis by cancer type in the multivariate
studies showed that a high NLR yielded worse OS in NSCLC
(HR=1.192, 95%CI: 1.061-1.399; Pheterogeneity=0.003) and
SCLC (HR=1.550, 95%CI: 1.156-2.077; Pheterogeneity=0.625).
The cancer type in the univariate studies was NSCLC only.
In the subgroup analysis by ethnicity, regardless of whether
the patients were Asian or Caucasian, an elevated NLR
remained a poor predictor of OS in multivariate studies
171 records  identified 
through database 
Records
screened (n=63)
108 records excluded 
(not relevant)
Review, letter, not full 
text in English, 
duplicate studies 
(n=22)
Failed to present NLR 
specific data for OS or 
absence of key information 
for estimating HR  
(n=27)
41 full-text 
articles assessed
14 studies included in 
the meta-analysis
Figure 1 - Methodological flow diagram of the meta-analysis.
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(Caucasian: HR=1.545, 95%CI: 1.052-2.269; Pheterogeneity=0.005;
Asian: HR=1.261, 95%CI: 1.092-1.547; Pheterogeneity=0.021)
and univariate studies (Caucasian: HR=1.722, 95%CI: 1.360-
2.179; Pheterogeneity=0.133; Asian: HR=1.661, 95%CI: 1.419-
1.945; Pheterogeneity=0.036).
Considering different cut-off values, these studies used
two subsets of NLR cut-offs and revealed similar results.
The NLR was found to be a negative prognostic marker for
the outcome of OS in multivariate studies (NLRX4:
HR=1.646, 95%CI: 1.319-2.053; Pheterogeneity=0.247; NLRo4:
HR=1.221, 95%CI: 1.016-1.468; Pheterogeneity=0.082) and
univariate studies (NLRX4: HR=1.500, 95%CI: 1.111-2.025;
Pheterogeneity=0.262; NLRo4: HR=2.043, 95%CI: 1.497-2.789;
Pheterogeneity=0.017).
Further analysis of studies evaluating OS by sample size
(studies with more than 200 cases were classified as ‘‘large’’,
and studies with less than 200 cases were classified as
‘‘small’’) also revealed that a high NLR remained a worse
prognostic marker regardless of the sample size (large:
HR=1.608, 95%CI: 1.186-2.179; Pheterogeneity=0.082; small:
HR=1.090, 95%CI: 1.034-1.131; Pheterogeneity=0.103) in multi-
variate studies and (large: HR=2.018, 95%CI: 1.229-3.315;
Pheterogeneity=0.016; small: HR=1.736, 95%CI: 1.403-2.148;
Pheterogeneity=0.211) in univariate studies.
Heterogeneity
Meta-regression analysis was performed to explore the
potential source of heterogeneity among multivariate and
univariate studies for OS using variables such as the year of
publication, ethnicity, cancer type, cut-off value and sample
size. In multivariate studies, the results showed that year of
publication (p=0.193), ethnicity (p=0.573), cancer type
(p=0.407), cut-off value (0.116) and sample size (p=0.183)
did not contribute to the source of heterogeneity. The same
results were shown in the univariate studies; the year of
publication (p=0.146), ethnicity (p=0.963), cut-off (0.457) and
sample size (p=0.795) also did not contribute to the source of
heterogeneity.
Table 1 - Characteristics of all included studies.
Study Year Country Ethnicity Number Type Method Stage Cut-off Follow-up (months)
Teramukai (23) 2009 Japan Asian 388 NSCLC M III/IV 4.744 18.9 (2.3-57.0)
Kacan (24) 2014 Turkey Caucasian 299 NSCLC M I-IV 5 NA
Yao (25) 2013 China Asian 182 NSCLC U III/IV 2.63 NA
Lee (26) 2012 Korea Asian 199 NSCLC M/U III/IV NA 36 (33.6-37.9)
Wang (27) 2014 China Asian 114 SCLC M NA 3 NA
Cedre´s (28) 2012 Spain Caucasian 171 NSCLC U IV 5 9.1 (1-70.37)
Unal (29) 2013 Turkey Caucasian 94 NSCLC U NA 3.44 NA
Pinato (30) 2014 UK Caucasian 220 NSCLC M/U I-III 5 NA
Kang (31) 2014 USA Caucasian 187 SCLC M NA 4 40.28 (2.60-89.26)
Cannon (32) 2014 USA Caucasian 59 NSCLC U I1 2.98 17
Tomita (33) 2011 Japan Asian 284 NSCLC M/U I-III 2.5 60.7-131.7
Sarraf (34) 2009 UK Caucasian 177 NSCLC M I-IV 3.81 29 (8-56)
Liao (35) 2013 China Asian 59 NSCLC M I-III NA 30 (8-40)
Tomita (36) 2012 Japan Asian 301 NSCLC U I-III 2.5 NA
NSCLC: non-small cell lung cancer; SCLC: small-cell lung cancer; M: multivariate; U: univariate.
Table 2 - Meta-analysis results.
Outcome Variable Number of studies Model HR(95%Cl) Pheterogeneity
OS All 14
MULTIVARIATE 9 Random 1.243 (1.106-1.397) 0.001
Cancer type
NSCLC 7 Random 1.192 (1.061-1.339) 0.003
SCLC 2 Fix 1.550 (1.156-2.077) 0.625
Ethnicity
Asian 5 Random 1.261 (1.029-1.547) 0.021
Caucasian 4 Random 1.545 (1.052-2.269) 0.005
Cut-off
X4 4 Fix 1.646 (1.319-2.053) 0.247
o4 3 Random 1.221 (1.016-1.468) 0.082
Sample size
Large 4 Random 1.608 (1.186-2.179) 0.082
Small 5 Fix 1.090 (1.034-1.131) 0.103
UNIVARIATE 8 Random 1.867 (1.487-2.344) 0.047
Ethnicity
Asian 4 Random 1.890 (1.301-2.744) 0.036
Caucasian 4 Fix 1.722 (1.360-2.179) 0.133
Cut-off
X4 2 Fix 1.500 (1.111-2.025) 0.262
o4 5 Random 2.043 (1.497-2.789) 0.017
Sample size
Large 3 Random 2.018 (1.229-3.315) 0.016
Small 5 Fix 1.736 (1.403-2.148) 0.211
NSCLC: non-small cell lung cancer; SCLC: small-cell lung cancer.
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Publication bias and sensitivity analysis
We conducted leave-one-out sensitivity analysis by remov-
ing one study per time to check if any individual study
affected the results. The result patterns were not obviously
affected by any single study in either the univariate or
multivariate group (Figures 3, 4). Begg’s funnel plot and
Egger’s linear regression tests were used to evaluate
publication bias. In the univariate studies, the results did
not show any evidence of publication bias (p=0.711 for
Begg’s test, and p=0.141 for Egger’s test). However, publica-
tion bias was found in the multivariate studies (p=0.002 for
Egger’s test and p=0.251 for Begg’s test and). Therefore, a
trim and fill method was used to evaluate the asymmetry in
the funnel plot. The recalculated pooled HRs with presumed
missing studies did not significantly change for multivariate
studies (HR=1.118, 95%CI: 1.002–1.233; Pheterogeneity=0.026;
Figure 5), indicating the stability of the results.
’ DISCUSSION
Systemic inflammation appears to play a pivotal role in the
progression of numerous cancers by promoting tumor
angiogenesis, tumor metastasis and cancer cell proliferation
and by affecting the tumor response to systemic treatment
(11). The NLR, a combination of circulating neutrophil and
lymphocyte counts, serves as a representative index of
systemic inflammation. Moreover, because it is calculated
from peripheral blood test results, the NLR is a readily
available biomarker of systemic inflammation that may
predict the prognostic outcome of patients. Indeed, recent
studies have evaluated the predictive value of the NLR in
various types of cancers (16-19). Our current study aimed to
evaluate the role of the NLR in lung cancer, and to the best of
our knowledge, it is the first meta-analysis to investigate the
prognostic role of the NLR in lung cancer.
This meta-analysis, including 14 studies with 2,734 lung
cancer cases, showed that an elevated NLR indeed predicted
worse OS, regardless of whether the HRs were calculated
from multivariate or univariate analysis. Subgroup analysis
showed that a high NLR yielded a worse OS in NSCLC and
SCLC based on multivariate analysis. The cancer type of the
studies using univariate analysis was NSCLC only. In the
subgroup analyses by ethnicity, we found that regardless of
whether patients were Asian or Caucasian, an elevated NLR
was still a poor predictor of OS in both multivariate and
univariate analyses. Considering different cut-off values,
these studies using two subsets of NLR cut-offs revealed
similar results, showing that the NLR was a negative
NOTE: Weights are from random effects analysis
.
.
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Figure 2 - Forrest plots of studies evaluating HRs of the NLR for OS.
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Figure 3 - Effect of univariate studies on the pooled HR for the NLR and OS of patients.
Figure 4 - Effect of multivariate studies on the pooled HR for the NLR and OS of patients.
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prognostic marker for the outcome of OS regardless of the
analysis method. Further analysis by sample size also revealed
the same results. Meta-regression analysis was performed
using variables such as the year of publication, ethnicity,
cancer type, cut-off value and sample size; however, none of
these variables contributed to heterogeneity.
The NLR has been related to patient prognosis in
numerous cancers, although the specific mechanism for this
relationship remains incompletely understood. Myeloid cells
are known to play a critical role in tumor pathogenesis by
promoting cancer cell proliferation, tumor angiogenesis, cell
invasion, and metastasis (37). In particular, tumor-derived
inflammation can increase myelopoiesis with defective
myeloid cell differentiation and proliferation by regulating
the bone marrow and spleen, leading to the accumulation of
immature myeloid cells in the peripheral circulation (38). In
the context of cancer-mediated myelopoiesis, the neutrophil
precursors myelocytes and promyelocytes proliferate and are
released into the peripheral blood. Neutrophils are the most
abundant granulocytes, which account for most peripheral
white blood cells (37). Thus, the prognostic and predictive
value of peripheral neutrophils as an independent index or
as part of the NLR in cancers is apparent, and enhanced
neutrophil responses and/or lymphocyte suppression, lead-
ing to a high NLR, might promote tumor progression and
inhibit the antitumor immune response.
Our study has several limitations that should be carefully
considered. First, the studies included in the analysis were
full texts in English and were identified by searching the
PubMed and Web of Science databases. Thus, publication
bias cannot be excluded, although it did not affect the results
according to the trim and fill method. In addition, marked
heterogeneity of the studies was found; this may have been
caused by the year of publication, ethnicity, cancer type, cut-
off value and sample size. However, no variables listed
above that were analyzed in the meta-regression analysis
contributed to the observed heterogeneity. In fact, the
existence of heterogeneity may have resulted from a variety
of other factors. Due to the lack of detailed data, we could
not use other clinical parameters in the meta-regression
analysis. Additionally, the number of included studies was
not large enough for part of the subgroup analysis; for
example, only two studies investigated the NLR for OS in
SCLC, and only two univariate studies with a small sample
size (less than 100 cases was classified as ‘‘small’’) yielded a
trend of a poor prognostic role of the NLR for OS. In the
future, more well-designed studies are needed to present
more reliable results.
In conclusion, despite the limitations listed above, the
synthesized evidence from published articles revealed that
elevated NLR was a poor predictor of survival in patients
with lung cancer. The NLR is an easily available blood test
and may serve as a useful prognostic biomarker in lung
cancer that does not require any additional resources for
routine use. Nevertheless, the clinical utility of the NLR must
still be confirmed in future analyses.
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